XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Former Agreement with Eli Lilly and Company
6 Months Ended
Jun. 30, 2021
Former Agreement with Eli Lilly and Company  
Former Agreement with Eli Lilly and Company

6. Former Agreement with Eli Lilly and Company

On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the “Lilly Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which the Company agreed to use its proprietary

FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause.

The Company recognized revenue under the Lilly Agreement of $22.4 million for the six months ended June 30, 2020. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company.